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Abstract:  The four genetically divergent dengue virus (DENV) types are traditionally classified 50 
as serotypes.  Antigenic and genetic differences among the DENV types influence disease 51 
outcome, vaccine-induced protection, epidemic magnitude, and viral evolution.  We 52 
characterized antigenic diversity in the DENV types by antigenic maps constructed from 53 
neutralizing antibody titers obtained from African green monkeys and after human vaccination 54 
and natural infections.  Genetically, geographically, and temporally, diverse DENV isolates 55 
clustered loosely by type, but we found many are as similar antigenically to a virus of a different 56 
type as to some viruses of the same type.  Primary infection antisera did not neutralize all viruses 57 
of the same DENV type any better than other types did up to two years after infection and did 58 
not show improved neutralization to homologous type isolates.  That the canonical DENV types 59 
are not antigenically homogenous has implications for vaccination and research on the dynamics 60 
of immunity, disease, and the evolution of DENV.!  61 
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Main text: Dengue virus (DENV) infects up to 390 million people each year, and of the 96 62 
million individuals who develop an acute systemic illness, approximately 500,000 experience 63 
potentially life-threatening complications, including hemorrhage and shock (1, 2).  The four 64 
genetic DENV types have long been thought to exist as four serotypes, and the antigenic 65 
differences between the types are believed to have a key role in the severity of disease, epidemic 66 
magnitude, viral evolution, and design of vaccines (3–5).  67 
 The description of DENV types as serotypes originated with the observation that the 68 
human immune response following primary DENV infection fully protected against challenge 69 
with viruses of the homologous type but only partially, and transiently, protected against 70 
challenge by viruses of a heterologous type (6).  This finding was supported by in vitro 71 
neutralization experiments in which each DENV type was on average better neutralized by 72 
homologous than heterologous DENV infection antisera (7).  The immune response immediately 73 
after a primary DENV infection varied from individual to individual, but generally was 74 
characterized by high levels of neutralizing antibody titers to multiple DENV types.  The 75 
neutralizing response was observed to become more DENV type-specific over time (8).  It was 76 
later shown that antibodies to a heterologous DENV type could enhance infection in vivo and 77 
were associated with increased risk of severe disease in nature (9, 10).  Although antigenic 78 
variability was observed within DENV types from the earliest studies, this variation is generally 79 
considered to be substantially less than the differences between types, and not thought to modify 80 
type-specific protection (11, 12).  Together, the DENV types clearly form an antigenic subgroup 81 
within the Flaviviridae (13, 14).  Analyses of envelope (E) proteins, and later full genomes, 82 
showed that the four types are as genetically divergent among themselves as sequences assigned 83 
to different viruses within the genus Flavivirus (15).  These deep evolutionary divergences 84 
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between DENV types were evident in the phylogenetic tree of the genetically diverse E-gene 85 
sequences of the viruses we investigated here (Fig. 1A; fig. S1; and table S1) (16).  Similarly, a 86 
map of amino acid differences between the E proteins revealed four compact, segregated types 87 
(Fig. 1B and fig. S2), as the number of amino acid substitutions between heterologous types far 88 
exceeded the maximum difference within a type.   89 
  However, investigations that rely on the classification of DENV into serotypes do not 90 
fully explain clinical and epidemiological phenomena.  Despite this, antigenic properties are still 91 
thought to play a critical role in the biology of DENV infections.  One hypothesis is that 92 
antigenic differences are critical, but that categorization by serotype alone is too coarse a 93 
measure.  For example, differences in epidemic magnitude might be determined not only by the 94 
serotype but also by the antigenic differences between the particular infecting viruses that 95 
populations experience during sequential epidemics.  Antigenic variation within and among the 96 
DENV types has also been hypothesized, in addition to intrinsic viral fitness and other factors, to 97 
explain phenomena including extinction and replacement of previously successful lineages and 98 
variation in disease outcome caused by genetically similar viruses (17–19).  Here, we empirically 99 
test the antigenic relationships among a panel of diverse DENV isolates and re-examine the 100 
serotype concept. 101 
Antigenic differences among viruses are caused by amino acid differences that lead to 102 
structural changes on viral proteins that modify antibody binding.  The structural effect of such 103 
amino acid substitutions is difficult to predict from genetic sequences alone.  In some instances 104 
substitutions have no antigenic effect, sometimes single substitutions cause substantial antigenic 105 
change, and other times it takes multiple substitutions (20, 21).  Thus today, antigenic differences 106 
must be determined by phenotype, including by an antibody neutralization assay (13).!!Most 107 
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often, viruses are measured against multiple sera to form a table of neutralization data from 108 
which antigenic relationships are inferred (22).!!However, such inferences are notoriously 109 
difficult to make, and this has hindered the reliable systematic antigenic characterization of 110 
DENV.  The difficulties are caused by random error, the use of diverse methods among 111 
laboratories, and the intrinsic variability among immune sera due to differences in hosts and 112 
infection histories (23, 24).  Moreover, neutralization data often contain apparent contradictions 113 
that are difficult to interpret, such as higher-than-homologous titers and sera that similarly 114 
neutralize multiple DENV types.!115 
Previous antigenic analyses of DENV have addressed such challenges by using 116 
monoclonal antibodies, averaging responses of many individuals, or excluding sera with unusual 117 
patterns of reactivity.  Despite careful work, these approaches have not produced a unified 118 
framework for understanding patterns across large neutralization data sets.  Antigenic 119 
cartography is a method that positions viruses and antisera as points in a map, such that the 120 
distance between each virus and antiserum is derived from the corresponding neutralization titer 121 
in the tabular data. This method exploits variation in host responses to better triangulate the map, 122 
reduces the effect of some measurement errors because each virus is measured against multiple 123 
antisera (and vice versa), and has been shown to accurately interpret apparent contradictions in 124 
the data (25). 125 
We formed the Dengue Antigenic Cartography Consortium, an open collaboration of 126 
international research laboratories, to establish empirically how DENV types relate to one 127 
another antigenically.  Thirty-six African green monkeys (Chlorocebus sabaeus, hereafter NHP) 128 
were experimentally inoculated with diverse DENV isolates, and their sera were tested for 129 
neutralizing antibody potency against the genetically (all known genotypes), temporally (1944-130 
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2012), and geographically (20 countries) diverse panel of DENV isolates shown in Fig. 1 (table 131 
S1).  Serum samples were taken three months post-inoculation, and titrations were conducted 132 
using an immunofocus reduction neutralization test on mosquito cells (C6/36, Aedes albopictus) 133 
(tables S2-S7 and fig. S3) (16, 26).  A conventional interpretation of the raw antibody 134 
neutralization titers was consistent with previous observations, both for DENV and for other 135 
flaviviruses: antisera were generally able to neutralize viruses of the infecting type better than 136 
heterologous types.   137 
The cartographic analyses fit these data with low error and were internally consistent 138 
(figs. S4, S6, and S7).  Only 1% of map distances differed by more than four-fold from the 139 
measured titer (table S8).  The positions of viruses and antisera were robust to different methods 140 
of calculating neutralization titers and to the exclusion of outliers (figs. S5, S8-S12 and table 141 
S10).  Maps made with random subsets of the data set could predict excluded titers within two-142 
fold error (r=0.90 for the relation between all measured and predicted titers) (table S9). 143 
Our analyses showed that the DENV isolates in our panel did group according to current 144 
serotype classification (Fig. 2), and the majority of viruses neighboring any given virus are of the 145 
same DENV type.  However, many of the viruses were positioned as close to a virus of another 146 
DENV type as to some viruses of their own type, and the distance within and between types was 147 
comparable.  Similarly, while neutralizing antisera responses clustered closely to viruses of the 148 
homologous type, almost all were at least as close to a heterologous-type isolate (table S11, table 149 
S12).  150 
To examine these findings in detail, we evaluated whether the observed antigenic 151 
diversity of the virus types was also observed with human antisera and over time, and whether 152 
the neutralizing responses of individual antisera became increasingly type-specific over time.   153 
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 We titrated human antisera derived from vaccination with a live-attenuated chimeric 154 
DENV vaccine against the genetically diverse DENV panel.  Individuals lacking detectable 155 
neutralizing antibodies against DENV or other flaviviruses were each inoculated with one 156 
monovalent component of the National Institutes of Health DENV vaccine (n=40 in total, 10 per 157 
DENV type).  Antisera drawn 42 days post-injection were titrated against the DENV panel 158 
(n=36) using the neutralization test on mosquito cells. The resulting antigenic map is consistent 159 
with the NHP map in that the distance between DENV types was equivalent to the spread within 160 
type, and the overall orientation of DENV1-4 was the same (Fig. 3A).   161 
We measured the antigenic relationships among the DENV panel as recognized by 162 
antisera drawn from naturally-infected individuals, who had neutralizing responses 163 
representative of the cohort study from which they were selected.  Serum samples drawn from 20 164 
Nicaraguan children in the year following their first DENV infection were titrated, using the 165 
neutralization test on mosquito cells, against 14 viruses that captured the breadth of variation 166 
seen in the DENV panel in Fig. 2.  Again, the antigenic distances among the DENV types were 167 
similar to those observed with NHP and human vaccine antisera, although the DENV4 cluster 168 
was positioned adjacent to DENV1 and DENV2 (Fig. 3B). 169 
We also analyzed neutralization data from other studies that had used antisera from 170 
monovalent vaccine recipients and naturally infected human travelers, as well as different 171 
neutralization assays (22, 27, 28). Again, the antisera from these studies also recognized the 172 
antigenic relationships among the DENV isolates similarly to the three-month NHP antisera 173 
(figs. S23-S25).  174 
The early antibody response is assumed to broadly neutralize all DENV types, but over 175 
time cross-type neutralization is thought to be lost so that the antibody response remaining in the 176 
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months to years after infection only potently neutralizes isolates of the infecting type (8, 29, 30).  177 
We compared how antisera taken at various time points after infection recognize antigenic 178 
relationships among the DENV panel.  The human antisera used to make the antigenic maps 179 
described above were taken at various times following infection, ranging from 42 days for the 180 
monovalent vaccine antisera to more than one year for the natural infection antisera.  We also 181 
made an antigenic map of a published neutralization data set of 44 DENV isolates titrated with 182 
one-year post-inoculation monkey antisera and found a similar range of antigenic variants among 183 
the four DENV types (fig. S26) (12).   Thus, in maps made with early (one month) as well as late 184 
convalescent (three months to one year) antisera, the antigenic relationships among diverse 185 
DENV isolates were similar to those observed with three-month NHP antisera. 186 
We tested if the patterns of antigenic recognition of the antisera from serially sampled 187 
individuals changed with time.  We titrated antisera from the experimentally inoculated NHPs 188 
one month (n=36) and five months (n=16) post-infection against the DENV panel.  As expected, 189 
the magnitude of the neutralizing titers generally dropped between one, three, and five months 190 
(table S14).  However, viruses on the one and five-month antigenic maps showed the same 191 
orientation of types as the three-month antisera.  At one month after infection, 55%, and at five 192 
months after infection, 41% of the viruses, respectively, clustered as closely to a virus in a 193 
heterologous type as to some viruses of the same type (Fig. 4A and B; table S11; table S13; and 194 
table S15).  The antigenic relationships among isolates were conserved across time-points (fig. 195 
S13).   We thus found that the antigenic relationships among the isolates in the DENV panel 196 
were recognized similarly by early and late convalescent antisera from the same individuals.  197 
  We measured changes in neutralizing type-specificity for each NHP by comparing the 198 
antiserum positions in the one, three, and five-month antigenic maps.  The antiserum positions 199 
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shifted (on average, greater than four-fold) between one month and three months, consistent with 200 
the period of somatic hypermutation and selection for affinity matured B cells (Fig. 4A and fig. 201 
S14).  However, few antisera showed improved neutralization of the infecting DENV type 202 
relative to heterologous types between one and three months.   The antiserum positions changed 203 
minimally between three months and five months, despite a significant decline in the magnitude 204 
of titers over that period, in some cases below the assay limit of detection (Fig. 4B and table 205 
S14).  Thus, we did not observe a systematic shift toward increasing neutralizing specificity to 206 
viruses of the infecting type nor decreasing specificity toward heterotypic viruses (fig. S15 and 207 
fig. S21).  208 
Published studies of neutralizing responses in the first year after experimental inoculation 209 
also reported stability of neutralization specificity.  In one study, the ratio between homologous 210 
and heterologous neutralizing titers for 16 Rhesus monkeys between 4-13 months after 211 
experimental inoculation was remarkably consistent.  NHPs that were initially type-specific 212 
remained so, while those that exhibited early cross-type titers maintained titers to those types to 213 
the end of the study period (fig. S28) (31).  A second study following the neutralizing responses 214 
of Aotus nancymae monkeys for 1-4 months to DENV1 and DENV2 isolates showed similarly 215 
stable neutralization specificity to the infecting type and heterologous types (fig. S29) (32). 216 
We further analyzed the neutralizing responses in the natural human infection data set to 217 
look at the type-specificity of antisera obtained during the first two years after infection.  The 218 
antisera in the map in Fig. 3B ranged in neutralizing type-specificity, with 55% of antisera 219 
responses clustering as closely to a heterologous isolate as some homologous isolates.   For each 220 
individual, the serum position in Fig. 3B, made with titrations conducted on mosquito cells, 221 
closely corresponded to the serum position in the map made with titrations using human cells 222 
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expressing the DENV attachment factor, DC-SIGN (Fig. 3B and fig. S16).   The position of the 223 
DENV4 cluster was between DENV1 and DENV2 on both maps (Fig. 3B and fig. S16).  We 224 
compared the antibody titrations after one and two years for each individual, and found that all 225 
maintained the pattern of neutralization, including cross-neutralization, observed in the first year 226 
after infection (fig. S17 and S18).  Thus, neutralizing antibody responses in natural human 227 
DENV infections did not show a trend toward increasing type-specificity even two years after 228 
infection. 229 
 Type-specific and cross-reactive neutralizing antibodies are thought to target distinct viral 230 
structures, and thus potentially may produce different antigenic maps (33).  We therefore tested 231 
whether cross-reactive neutralizing antisera recognized different antigenic relationships among 232 
the DENV panel than type-specific neutralizing responses, using the serum positions of the 233 
monovalent vaccine map (Fig. 3A).  Despite the fact that all ten individuals for each DENV type 234 
were inoculated with the same vaccine component, the antisera responses to the isolates varied.  235 
Collectively, the antisera provided a coherent description of antigenic patterns among the isolates 236 
(fig. S19).  The relationships among the DENV panel changed minimally between maps made 237 
with only the most central, cross-reactive 20 antisera or only the most peripheral, type-specific 238 
20 antisera (fig. S20 and fig. S22).  Thus, the DENV type-specific and cross-reactive neutralizing 239 
responses recognized the same antigenic relationships among the DENV panel. 240 
 The antigenic characterization of any pathogen relies on the biological relevance of the 241 
assay used to generate the data.  Both recent and historical studies have found significant 242 
associations between pre-infection neutralization titers and DENV viremia or infection outcome 243 
(34–37); however, other studies have been inconclusive (38, 39).  Thus, the identification of 244 
immune correlates of protection including, but not exclusively, potently neutralizing antibodies, 245 
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is an active area of research for DENV (40–42).  Notably, the antigenic patterns in our data are 246 
similar to those in antigenic maps we made of DENV antibody neutralization data from other 247 
published studies using different cell lines, virus preparations, methods for detecting infected 248 
cells, and plaque or immunofocus reduction end-points (figs. S23-S27) (12, 19, 22, 27, 28).  We 249 
also found that the human antisera from natural infections titrated on mosquito cells showed 250 
similar neutralization profiles to those titrated on human cells (fig. S16 and S18).  The antigenic 251 
variation we observed is thus not limited to the assay or samples that we used. 252 
 While overall, prior immunity to a heterologous DENV type still remains the strongest 253 
risk factor for disease, there is evidence that neutralizing responses to the particular DENV 254 
lineages circulating in a population modifies the magnitude and severity of epidemics caused by 255 
subsequent infecting lineages (17, 18).  In one study, cross-type neutralization provided by prior 256 
DENV1 immunity correlated with a mild epidemic caused by one lineage of DENV2, but 257 
showed no neutralization of other DENV2 lineages that in immunologically similar populations 258 
caused severe epidemics (fig. S27) (19).  These, and our, studies highlight the importance of 259 
studying the specific relationship between antigenic distances as measured with neutralizing 260 
antibody titers and protection.  The approach described here, in combination with global 261 
surveillance of the genetic, antigenic, and clinical features of DENVs as well as further detailed 262 
studies of natural infection and vaccination-derived protection, has the potential to inform 263 
whether vaccination protects against circulating isolates as well as recognize gaps in vaccine-264 
induced protection should they emerge over time.   265 
 The antigenic analyses shown here using one, three, and five-month NHP antisera, 266 
human monovalent vaccine antisera, late-convalescent human natural infection antisera, and 267 
published neutralization data show that the DENV types do not fall into order as distinct 268 
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serotypes.  We have found that while DENV isolates are usually located closer to other viruses 269 
of the same type, some viruses, both modern and historical, have greater antigenic resemblance 270 
to viruses of a different type than to some viruses of the same type.  We find that primary 271 
infection neutralizing antibody titers, although they drop in magnitude, do not systematically 272 
become more type-specific in the year after primary infection.  As expected, individuals infected 273 
with the same or different antigens have variable patterns of neutralization, but cross-neutralizing 274 
responses consistently recognize the same antigenic relationships within the DENV panel as do 275 
the neutralizing responses that are most type-specific.  These findings shift our understanding of 276 
the antigenic properties of DENV, enable more detailed study of the antigenic determinants of 277 
clinical severity, epidemic magnitude, and DENV evolution, and provide additional methods for 278 
the selection of future vaccine strains and global surveillance of the antigenic dynamics of 279 
dengue viruses.   280 
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Figure legends 281 
Fig. 1.  Genetic analyses of the DENV panel (n=47).  (A) Phylogenetic tree showing the 282 
evolutionary relationships of DENV E gene sequences. Sequences were aligned with MAFFT, 283 
and a maximum likelihood tree (ML) was estimated using a general time reversible model, 284 
accounting for both among site rate variation and invariant sites (GTR+G4+I).  Bootstrap support 285 
values of at least 75% are shown. (B) Amino acid map of dengue E protein sequences (493-495 286 
amino acids in length).  The total amino acid differences between pairs of E sequences 287 
correspond to distances between points on the geometric display.  288 
Fig. 2.  Antigenic map of the DENV panel (n=46) titrated against three-month post-infection 289 
African green monkey antisera (n=36).  Each unit of antigenic distance (length of one grid-290 
square side, measured in any direction) is equivalent to a two-fold dilution in the neutralization 291 
assay.  Each antiserum (open shape) and virus (closed shape) is colored according to the 292 
infecting genetic type (16). The size and shape of each point is the confidence area of its 293 
position.   294 
Fig. 3. Human primary infection antigenic maps.  (A) Antisera from individuals inoculated with 295 
each monovalent component of the NIH live vaccine (10 per group) were drawn 42 days post-296 
infection and titrated against 36 viruses in the DENV panel.  (B) Antisera from 20 Nicaraguan 297 
children drawn in the year after their first DENV infections were titrated against an antigenically 298 
diverse subset of the DENV panel (n=14).   299 
Fig. 4.  Antigenic maps of the DENV panel made with antisera drawn from NHPs one and five 300 
months post-infection.  (A) An antigenic map of 47 DENV isolates titrated against 36 NHP 301 
antisera drawn one month post-infection.  Colored arrows (DENV1=yellow, DENV2=blue, 302 
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DENV3=green, DENV4=red) show the change in antiserum positions between one and three 303 
months. The black arrows show the average shift in serum position for each DENV type.  The 304 
star denotes the antigenic center for each DENV type. (B) An antigenic map of 37 DENV 305 
isolates titrated against 16 NHP antisera drawn five months post-infection.  Arrows point from 306 
positions of antisera at three months to the corresponding five-month positions.    307 
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